Integrative practitioners are in a unique position to help patients make decisions about medications such as Semaglutide (Ozempic). It's important that we deeply understand the data on medications so we can support patients (and not misinform them).   In this podcast we cover the STEP 1 Extension trial by Wilding. (**Note that I misquote in the recording and call it the STEP 5 extension trial).   We discuss topic such as   The morality of obesity medication and ridding yourself of bias. Cohort data - what they give us and what they don't. The STEP 1 extension trial that examines weight regain, cholesterol and blood pressure 1 year after discontinuing Semaglutide. Our possible future role in supporting these patients, but where we need more information.     Our members will be receiving a full intensive program on Insulin resistance and diabetes (including discussion on medication) in the spring of 2023. If you are not a member of The Confident Clinician, you can join the wait list to learn when our membership is available in the future.       DeSouza, C. et al. Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. J Clin Endocrinol Metabolism 105, 543–556 (2019).   Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metabolism 24, 1553–1564 (2022).